Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more
Adaptimmune Therapeutics Plc (ADAP) - Total Liabilities
Latest total liabilities as of June 2025: $201.59 Million USD
Based on the latest financial reports, Adaptimmune Therapeutics Plc (ADAP) has total liabilities worth $201.59 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Adaptimmune Therapeutics Plc - Total Liabilities Trend (2011–2024)
This chart illustrates how Adaptimmune Therapeutics Plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Adaptimmune Therapeutics Plc Competitors by Total Liabilities
The table below lists competitors of Adaptimmune Therapeutics Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KAVDEFENCE
NSE:KAVDEFENCE
|
India | ₹435.44 Million |
|
Chinese People Holdings Company Limited
F:KEH
|
Germany | €586.19 Million |
|
Alaska Energy Metals Corporation
OTCQB:AKEMF
|
USA | $1.93 Million |
|
PPK Group Limited
PINK:PLPKF
|
USA | $31.70 Million |
|
Vext Science Inc
OTCQX:VEXTF
|
USA | $59.68 Million |
|
Eastwood Bio-Medical Canada Inc
PINK:EWOOF
|
USA | $1.47 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Adaptimmune Therapeutics Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adaptimmune Therapeutics Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adaptimmune Therapeutics Plc (2011–2024)
The table below shows the annual total liabilities of Adaptimmune Therapeutics Plc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $234.11 Million | -3.70% |
| 2023-12-31 | $243.10 Million | -1.59% |
| 2022-12-31 | $247.04 Million | -6.28% |
| 2021-12-31 | $263.58 Million | +139.81% |
| 2020-12-31 | $109.92 Million | +89.82% |
| 2019-12-31 | $57.91 Million | +93.98% |
| 2018-12-31 | $29.85 Million | -61.81% |
| 2017-12-31 | $78.16 Million | +14.32% |
| 2016-12-31 | $68.37 Million | +66.48% |
| 2015-12-31 | $41.07 Million | 0.00% |
| 2014-12-31 | $41.07 Million | -22.67% |
| 2013-12-31 | $53.11 Million | +1239.03% |
| 2012-12-31 | $3.97 Million | -3.03% |
| 2011-12-31 | $4.09 Million | -- |